Fiche centre
Excell Research, Inc.
Oceanside — United States
Essais liés4clinical trials
VilleOceansidelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07116499
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| K-645 100 mg | Migraine | Phase 2 | NCT07116499 | A Study of K-645 in the Treatment of Multiple Migraine Attacks | TERMINATED |
| Elismetrep (K-304) 2 mg | Migraine | Phase 2 | NCT06848075 | A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03777059 | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03939312 | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine | COMPLETED |